PIK3CA and ovarian cancer: In summary, our results presented in this study show that the specific inhibition of PI3K isoform p110β, but not p110α, is able to resensitize PTX-resistant cancer cells to PTX in vitro and in vivo, and represents a novel therapeutic strategy for overcoming the PTX-resistance in ovarian cancer.